The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link
The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
- Phase of development
- Approved
- Pre-registration & Phase III
- Phase II & Phase II/III
- Type of molecule
- Cell and gene therapies
- Monoclonal antibodies
- Proteins
- Peptides (recombinant)
- Vaccines
- Others
- Target therapeutic area
- Autoimmune disorders
- Blood disorders
- Bone disorders
- Genetic disorders
- Metabolic disorders
- Neurological disorders
- Oncological disorders
- Respiratory disorders
- Others
- Type of drug delivery system
- Large volume wearable injectors
- Autoinjectors
- Prefilled syringes
- Needle-free injectors
- Drug reconstitution systems
- Revenues from licensing deals
- Upfront payments
- Milestone payments
- Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the World
The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Adocia
- Ajinomoto Bio-Pharma Services
- Arecor
- Alteogen
- Ascendis Pharma
- Avadel Pharmaceuticals
- Camurus
- Creative BioMart
- Creative Biolabs
- DURECT
- Eagle Pharmaceuticals
- Halozyme Therapeutics
- MedinCell
- Xeris Pharmaceuticals
- Serina Therapeutics
Table of Contents
- Preface
- Executive Summary
- Introduction
- Subcutaneous Biologics: Current Market Landscape
- Case Study: Leading Subcutaneous Biologics
- Subcutaneous Formulation Technologies: Current Market Landscape
- Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
- Subcutaneous Formulation Technology Developers: Company Profiles
- Partnerships and Collaborations
- Subcutaneous Drug Delivery Systems: Current Market Landscape
- Swot Analysis
- Market Forecast and Opportunity Analysis
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List Of Companies And Organization
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
71832